124.55 9% 104.83 8% Investment in associated company 397.46 28% 483.96 36% Property, plant and equipment 644.04 46% 558.59 42% Biological assets – dairy cow 45.60 3% 44.28 3% Others 61.05 5% 61.09 4% Total
system of new medicines according to the additional standards SET forth by the Food and Drug administration. Therefore, it is necessary to use the capital to proceed the project amount 32,000,000 baht
from change in fair value of biological assets 9.70 Million Baht. The main cause is the value of economic trees that was recorded in the consolidated financial statements as at 31 December 2016
improvement. Other Transaction In Year 2018, the company recorded Baht 34.0 million from gain on changes in fair value less costs to sell biological asset, gain on sales deposits from land Baht 22.2 million and
cost to sale of biological assets. Financial Cost Financial cost in Quarter 2/2019 was Baht 8.5 Million decreased by Baht 1.3 Million or 13.1% from Q2/2018 mainly from bank loan repayment in 2018. Net
Transaction In Quarter 2/2018, the company recorded Baht 22.2 million from gain on sales of deposits for land, Baht 3.9 million from gain on changes in fair value less costs to sell biological asset and Baht
and internal control of subsidiaries improvement. Other Transaction In Quarter 3/2018, the company recorded Baht 4.0 million from gain on changes in fair value less costs to sell biological asset and
essential for economic development and sustainability. Applying science to Thailand?s resource abundance and biological diversity will bring about better quality of life and economic sustainable development
Constructions (2) Registration of 100 drugs formulas (54 formulas for human medicine and 46 formulas for animals) owned by the seller (3) Registration of special drug formulas, consisting of 12 formulas including
and Drug Administration (CFDA), which took around 2 months, that we have got CFDA in early 2018. Sales by product category Consolidated financial statements For the three months period ended March 31